Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female participants 18 to 75 years of age.
Clinical diagnosis of PN for at least 3 months prior to Screening visit.
Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.
Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.
Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous PN treatment.
Willingness to avoid pregnancy or fathering children.
You may not be if
Chronic pruritus due to a condition other than PN or neuropathic and psychogenic pruritus.
Diagnosis of PN secondary to medications.
Active AD lesions (signs and symptoms other than dry skin) within 3 months prior to Screening visit.
Women who are pregnant (or are considering pregnancy) or breastfeeding.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
Evidence of infection with TB, HBV, HCV or HIV.
History of failure to any topical or systemic JAK or TYK2 inhibitor as treatment of PN or any inflammatory disease.
Laboratory values outside of the protocol-defined ranges.
Clareo Health | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
